View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 3, 2017

Bayer’s copanlisib meets primary endpoint in Phase II trial to treat iNHL

German chemical and lifesciences firm Bayer has reported positive results from the Phase II CHRONOS-1 clinical trial of copanlisib for the treatment of indolent non-Hodgkin's lymphoma (iNHL) patients.

German chemical and lifesciences firm Bayer has reported positive results from the Phase II CHRONOS-1 clinical trial of copanlisib for the treatment of indolent non-Hodgkin's lymphoma (iNHL) patients.

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

Copanlisib is an investigational intravenous pan-Class I phosphatidylinositol-3-kinase (PI3K) inhibitor, which has predominant inhibitory activity against PI3K-α and PI3K-δ isoforms.

The company noted that the primary endpoint of a pre-specified objective response rate (ORR) was met in the trial.

The open-label, single-arm Phase II trial investigated the efficacy and safety of the product in 142 patients with relapsed or refractory iNHL, including follicular lymphoma (FL) who received a minimum of two prior therapies.

Bayer oncology strategic business unit executive vice-president and head Robert LaCaze said: "NHL is the tenth most common cancer worldwide and one of the most common cancers in the US.

"NHL is the tenth most common cancer worldwide and one of the most common cancers in the US."

"Despite treatment advances, most indolent NHL patients relapse after, or are refractory to, current therapies.

"The positive results from CHRONOS-1 are an important milestone and reflect the potential clinical utility of copanlisib in addressing the unmet medical need in patients with malignant lymphoma."

While the trial's primary endpoint was objective tumour response rate, the secondary endpoints included duration of response, overall survival, progression-free survival, quality of life and safety.

The US Food and Drug Administration (FDA) has granted fast-track designation for copanlisib in relapsed or refractory FL, as well as orphan drug designation (ODD) to treat FL.

The product has also obtained ODD for the treatment of patients with splenic, nodal, and extranodal subtypes of marginal zone lymphoma (MZL).

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena